United Therapeutics stock rises 12.6% in trading

United Therapeutics stock rises 12.6% in trading: the analysis positions LQDA, INSM and GOSS under pressure; confidence medium.

Analyzed 2026-10-01 — point-in-time, never revised. Outcomes are scored against SPY and published either way.

Who's next

▼ LQDA Liquidia — impact -93 · confidence medium · horizon immediate · 1st order
The infringement ruling removes Yutrepia's PH-ILD indication, reducing Liquidia's addressable launch revenue.
Chain: court finds Yutrepia infringes United Therapeutics patent → PH-ILD indication stripped from the Yutrepia label → addressable launch population shrinks sharply → Liquidia script volume and launch revenue fall
What would break the call: An appellate stay restoring the PH-ILD indication would reopen the full launch market for Yutrepia.
▼ INSM Insmed — impact -38 · confidence low · horizon quarters · 2nd order
Insmed faces a fortified inhaled treprostinil incumbent, which raises the commercial bar for its TPIP pulmonary hypertension program.
Chain: incumbent inhaled treprostinil keeps label breadth → entrenched prescriber habits strengthen in PH-ILD → TPIP must clear a higher efficacy bar → Insmed launch economics and timing look harder
What would break the call: Strong TPIP phase three data showing clear superiority would restore its commercial outlook regardless of the ruling.
▼ GOSS Gossamer Bio — impact -35 · confidence low · horizon quarters · 2nd order
Gossamer must fund seralutinib into a market where the incumbent retains exclusivity, weakening partnering terms and pricing leverage.
Chain: incumbent retains pulmonary hypertension exclusivity → competitive backdrop for seralutinib hardens → partner interest and deal terms weaken → Gossamer funding cost and dilution risk rise
What would break the call: A large pharma partnership on rich terms for seralutinib would disprove the weaker deal economics claim.
▼ TEVA Teva — impact -30 · confidence low · horizon weeks · 3rd order
Rising preference for United Therapeutics branded drugs cuts demand for generics and hurts Teva revenue.
Chain: branded inhaled treprostinil keeps PH-ILD patients → fewer patients move to lower cost options → generic treprostinil injection demand stays limited → Teva generic revenue in the category stays soft
What would break the call: Payers forcing step therapy through generic treprostinil would lift Teva volumes despite the ruling.
▼ KROS Keros Therapeutics — impact -28 · confidence low · horizon quarters · 2nd order
Keros values its pulmonary arterial hypertension asset against a stronger competitor, reducing licensing economics and deal probability.
Chain: incumbent exclusivity in pulmonary hypertension preserved → competitive bar for Keros PAH asset rises → partner valuation of the program declines → licensing economics and deal probability weaken
What would break the call: An announced out licensing deal with sizeable upfront payments would contradict weakened partnering economics.
▼ SNY Sanofi — impact -28 · confidence low · horizon quarters · 3rd order
Significant market shift toward United Therapeutics solutions reduces Sanofi sales in competitive pharmaceutical segments.
Chain: rare respiratory spending concentrates on branded Tyvaso → payer budgets tighten for other specialty respiratory drugs → marginal pressure on Sanofi respiratory portfolio → small effect on Sanofi specialty sales
What would break the call: Dupixent driven respiratory growth continuing unchanged would show no budget crowding effect.
▼ AZN AstraZeneca — impact -25 · confidence low · horizon quarters · 3rd order
Increased competition from United Therapeutics therapies reduces AstraZeneca drug pricing in overlapping indications.
Chain: inhaled treprostinil keeps interstitial lung disease patients → adjacent respiratory franchises face tighter formulary room → AstraZeneca overlapping respiratory pricing sees mild pressure → limited effect on AstraZeneca revenue
What would break the call: AstraZeneca reporting continued respiratory price stability would remove the pricing pressure argument.
▼ TENX Tenax Therapeutics — impact -25 · confidence low · horizon quarters · 2nd order
Tenax competes for the same specialist prescribers, and entrenched Tyvaso use lowers the commercial ceiling for levosimendan.
Chain: pulmonary hypertension specialists stay anchored on Tyvaso → prescriber bandwidth for new entrants narrows → levosimendan faces a lower commercial ceiling → Tenax financing and valuation weaken
What would break the call: Positive phase three levosimendan data in HFpEF linked PH would restore an independent commercial case.
▼ MRK Merck — impact -24 · confidence medium · horizon quarters · 2nd order
Entrenched inhaled treprostinil diverts pulmonary hypertension patients from Winrevair, slowing Merck's revenue growth.
Chain: Tyvaso retains exclusive PH-ILD positioning → patients stay on inhaled treprostinil regimens → fewer switches and add ons to Winrevair → Merck Winrevair uptake growth moderates
What would break the call: Winrevair quarterly sales beating consensus again would show no displacement from Tyvaso strength.
▼ PFE Pfizer — impact -13 · confidence medium · horizon quarters · 3rd order
United Therapeutics' inhaled therapy diverts pulmonary hypertension prescriptions from Pfizer, reducing its revenue.
Chain: inhaled treprostinil holds pulmonary hypertension patients → oral vasodilator starts grow more slowly → Pfizer legacy PAH products see weak demand → immaterial change to Pfizer revenue
What would break the call: Pfizer reports no pulmonary hypertension revenue line, so any product level evidence is absent.
▼ JNJ Johnson & Johnson — impact -10 · confidence low · horizon quarters · 2nd order
Actelion oral therapies cede share as inhaled treprostinil extends its label and holds patients on United Therapeutics regimens.
Chain: inhaled treprostinil extends patient retention → fewer patients escalate to oral Actelion regimens → Opsumit and Uptravi share erodes slowly → Johnson and Johnson pulmonary revenue softens
What would break the call: Uptravi sales continuing double digit growth would show no displacement from inhaled treprostinil.
▼ VTRS Viatris — impact -10 · confidence low · horizon quarters · 3rd order
Viatris generic treprostinil and oral PAH generics gain fewer switchers when branded inhaled therapy keeps patients locked in.
Chain: branded inhaled therapy retains PH-ILD patients → fewer patients cycle to generic alternatives → Viatris generic pulmonary volumes stay flat → complex generics revenue growth disappoints
What would break the call: Payers mandating generic step therapy in pulmonary hypertension would raise Viatris volumes.
▼ UNH UnitedHealth — impact -7 · confidence low · horizon quarters · 2nd order
Blocking a cheaper inhaled rival keeps specialty drug costs high, raising medical expense for UnitedHealth insurance members.
Chain: low cost inhaled alternative loses PH-ILD label → payers keep paying branded Tyvaso prices → specialty pharmacy cost per member stays high → UnitedHealth medical loss ratio faces pressure
What would break the call: Optum Rx negotiating deeper Tyvaso rebates would neutralize the cost increase.

Already moved

▲ UTHR United Therapeutics — impact +91 · confidence medium · horizon immediate · 1st order
The ruling restricts Yutrepia, protecting United Therapeutics' Tyvaso volume and pricing in pulmonary hypertension-associated interstitial lung disease.
Chain: ruling restricts a direct inhaled treprostinil rival → Tyvaso keeps sole PH-ILD label breadth → patient switching pressure and discounting ease → Tyvaso revenue and net price hold
What would break the call: A successful Liquidia appeal or design around restores competition and resumes Tyvaso price erosion.
▲ MNKD MannKind — impact +72 · confidence low · horizon quarters · 2nd order
MannKind collects royalties and manufacturing fees on Tyvaso DPI, so preserved exclusivity lifts its highest margin revenue line.
Chain: Tyvaso DPI exclusivity preserved by the ruling → United Therapeutics DPI volumes keep growing → MannKind collects royalties on those sales → high margin royalty and manufacturing revenue rises
What would break the call: A reversal that lets Yutrepia compete in PH-ILD would slow Tyvaso DPI royalty growth.
▲ GILD Gilead — impact +35 · confidence low · horizon weeks · 3rd order
Growing acceptance of pulmonary hypertension therapies from the United Therapeutics rise increases Gilead revenue.
Chain: rare disease sentiment improves after the ruling → pulmonary hypertension category attention increases → diversified large cap biopharma trades in sympathy → Gilead valuation moves modestly on sentiment
What would break the call: Gilead trading flat while UTHR rallies would show no sentiment transmission to this name.
▲ BMY Bristol Myers Squibb — impact +30 · confidence low · horizon quarters · 3rd order
Validation of the therapy class by United Therapeutics performance improves Bristol Myers Squibb drug uptake.
Chain: class validation lifts rare cardiopulmonary sentiment → investor interest in adjacent programs increases → Bristol Myers cardiovascular pipeline gains attention → modest multiple support with no revenue change
What would break the call: Bristol Myers guidance driven by oncology and Camzyos would overwhelm any pulmonary sentiment effect.
▲ CI Cigna — impact +15 · confidence low · horizon quarters · 2nd order
Specialty pharmacy dispensing of inhaled treprostinil stays concentrated in branded Tyvaso, keeping Accredo script revenue and service fees elevated.
Chain: branded Tyvaso keeps PH-ILD dispensing volume → specialty pharmacy scripts remain high priced → Accredo captures dispensing fees and spread → Cigna specialty services revenue holds
What would break the call: A lower cost inhaled rival winning broad label access would cut specialty revenue per prescription.
▲ CVS CVS Health — impact +13 · confidence low · horizon quarters · 2nd order
Branded Tyvaso dispensing sustains specialty pharmacy revenue and rebate economics as a cheaper inhaled rival loses label breadth.
Chain: branded Tyvaso retains PH-ILD dispensing share → specialty pharmacy handles high cost fills → CVS captures dispensing margin and rebate economics → specialty segment revenue stays elevated
What would break the call: Tyvaso moving to a narrow exclusive distributor outside CVS would remove this dispensing benefit.
▲ MEDP Medpace — impact +12 · confidence low · horizon quarters · 3rd order
Expanded pulmonary fibrosis and pulmonary hypertension development spending across rare disease sponsors raises clinical trial bookings for Medpace.
Chain: competitors must run larger differentiating trials → rare disease sponsors raise development spending → clinical research organizations win new bookings → Medpace backlog and revenue grow
What would break the call: Small biotech funding drying up would cut rare disease trial starts and offset the bookings gain.
▲ IQV IQVIA — impact +9 · confidence low · horizon quarters · 3rd order
Challengers need larger comparative trials against a fortified incumbent, lifting outsourced clinical development bookings at IQVIA.
Chain: competitors face a higher differentiation bar → pulmonary hypertension trials grow in size → contract research demand increases → IQVIA research and development solutions backlog rises
What would break the call: Biotech funding weakness cutting trial starts would reduce bookings despite the higher bar.
▲ TMO Thermo Fisher Scientific — impact +9 · confidence low · horizon quarters · 3rd order
Thermo Fisher sells reagents and fill finish capacity into growing treprostinil trial and commercial supply volumes.
Chain: treprostinil commercial and trial volumes keep rising → sponsors buy more reagents and fill finish capacity → Thermo Fisher bioproduction orders increase → pharma services revenue rises modestly
What would break the call: Continued pharma capital spending cuts would offset any incremental rare disease order flow.
▲ MCK McKesson — impact +8 · confidence low · horizon quarters · 2nd order
McKesson specialty distribution earns fees on high priced branded Tyvaso volume that stays protected from cheaper competition.
Chain: branded Tyvaso keeps PH-ILD volume → specialty distributors move high priced units → distribution fees scale with product value → McKesson specialty revenue holds steady
What would break the call: A shift to direct manufacturer distribution for Tyvaso would bypass McKesson entirely.
▲ WST West Pharmaceutical Services — impact +8 · confidence low · horizon quarters · 3rd order
West supplies containment and delivery components whose unit demand tracks rising inhaled treprostinil prescription volumes.
Chain: inhaled and parenteral treprostinil volumes grow → device and containment component demand follows → West ships more elastomer and delivery parts → West proprietary products revenue rises slightly
What would break the call: Customer destocking in high value components would swamp this small incremental volume.
▲ CRL Charles River Laboratories — impact +6 · confidence low · horizon quarters · 3rd order
Renewed preclinical work on next generation prostacyclin and PAH candidates supports Charles River discovery and safety assessment demand.
Chain: incumbent exclusivity pushes rivals toward new molecules → early stage pulmonary hypertension programs restart → preclinical safety and discovery services demand rises → Charles River revenue gains marginally
What would break the call: Continued biotech preclinical spending cuts would keep Charles River bookings in decline.

Sources

What happened

Horizon	Verdict	Top pick	Excess vs SPY
1 trading days	Mixed	—	—
5 trading days	Mixed	—	—

Related scenarios

Stocks in this scenario

LQDA · INSM · GOSS · TEVA · KROS · SNY · AZN · TENX · MRK · PFE · JNJ · VTRS · UNH · UTHR · MNKD · GILD · BMY · CI · CVS · MEDP · IQV · TMO · MCK · WST · CRL

News events · All scenarios · Pricing · Track record · Methodology · Map your own scenario